ASH 2021
American Society Of Hematology (Ash) Annual Meeting 2021
December 11-14, 2021 | Virtual
Blinatumomab as a new option for reinduction therapy with children and AVAs in low-risk first relapse of B-ALL
Pivotal results of phase 1/2 study: Novel mosunetuzumab elicits clinically durable response and deep remission in rrFL patients who underwent ≥2 prior lines of therapy
Adding ISA to standard RVD regimen as a potential new NDMM treatment
Evaluating efficacy and safety of D-RVd induction therapy for NDMM patients: An update of post 24 months of maintenance